PMS-FLUPHENAZINE DECANOATE LIQUID

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

FLUPHENAZINE DECANOATE

Saadav alates:

PHARMASCIENCE INC

ATC kood:

N05AB02

INN (Rahvusvaheline Nimetus):

FLUPHENAZINE

Annus:

100MG

Ravimvorm:

LIQUID

Koostis:

FLUPHENAZINE DECANOATE 100MG

Manustamisviis:

INTRAMUSCULAR

Ühikuid pakis:

1ML

Retsepti tüüp:

Prescription

Terapeutiline ala:

PHENOTHIAZINES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0110769002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2000-03-30

Toote omadused

_pms-FLUPHENAZINE DECANOATE Product Monograph _
_Page 1 of 31_
PRODUCT MONOGRAPH
Pr
PMS-FLUPHENAZINE DECANOATE
Fluphenazine Decanoate Injection, BP
25 mg/mL and 100 mg/mL
ANTIPSYCHOTIC
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite 100
November 14, 2013
Montréal, Québec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
September 18, 2014 CONTROL NO.:
170565
_pms-FLUPHENAZINE DECANOATE Product Monograph _
_Page 2 of 31_
PRODUCT MONOGRAPH
PMS-FLUPHENAZINE DECANOATE
Fluphenazine Decanoate Injection, BP
25 mg/mL and 100 mg/mL
THERAPEUTIC CLASSIFICATION
Antipsychotic
ACTION AND CLINICAL PHARMACOLOGY
The effects of pms-FLUPHENAZINE DECANOATE (fluphenazine decanoate) are
the same as those of
fluphenazine hydrochloride, however, the slow release of the decanoate
derivative of fluphenazine from the site
of injection results in a prolonged duration of action. Once released
in the blood, fluphenazine decanoate is
rapidly hydrolyzed by blood esterases with no attenuation of its
antipsychotic action. The onset of action
generally appears between 24 to 72 hours after injection, and the
effects of the drug on psychotic symptoms
become significant within 48 to 96 hours. Amelioration of symptoms
then continues for 1-8 weeks with an
average duration of 3-4 weeks. There is considerable variation in the
individual response of patients to this
depot fluphenazine and its use for maintenance therapy requires
careful supervision.
Like other phenothiazines, fluphenazine exerts activity at various
levels of the central nervous system as well as on
peripheral organ systems which accounts for the antipsychotic action
and side effects common to this class of drugs.
Indirect evidence indicates that the antipsychotic effects of
phenothiazines are linked to their effect in blocking
dopamine and other catecholamine receptor sites.
Fluphenazine differs from some phenothiazine derivatives in several
respects: it has less potentiating effect on
central nervous system depressants and anesthetics than do some of the
phenothiazines a